Earnings Releases·Nov 13, 2026, 7:20 AM ET

Jade Biosciences — Third Quarter 2026 Earnings Summary

Net loss widened to $35.1 million (vs. $25.2 million YoY) as total operating expenses rose to $39.6 million (vs. $27.4 million), driven by R&D and G&A increases; cash and investments grew to $475.7 million, sufficient to fund operations through Q4 2028.
JADE101 Phase 3 EVERGREEN trial is scheduled to initiate in Q4 2026 ahead of schedule, while JADE301 Phase 1 in healthy volunteers is also expected to begin in Q4 2026, supporting a pipeline of three clinical-stage programs entering 2027.
Management anticipates multiple clinical catalysts and readouts across the pipeline in 2027, including interim data for JADE101 in Q2 2027 and biomarker data for JADE201 later in the year.
Organizational changes include the expansion of Brad Dahms' role to Chief Financial Officer and Chief Business Officer, with no new M&A or capital return activities reported.